广州瑞领医药

Ruiling Pharmaceutical is a clinical-stage biopharmaceutical company based in Guangzhou, China, specializing in the development of high-end inhaled medications for respiratory diseases. The company focuses on complex inhalation formulations, including dry powder inhalers (DPI) and pressurized metered-dose inhalers (pMDI), to treat conditions such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. Ruiling's pipeline includes both improved generic drugs and innovative therapies designed to address the high technical barriers in respiratory drug delivery. By leveraging its proprietary technology platforms, the company aims to provide high-quality, affordable alternatives to global blockbuster respiratory products. Supported by prominent investors like Legend Capital and Hillhouse, the company is positioning itself as a leader in the Chinese respiratory drug market.